Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Co-Diagnostics, Inc. reported a quarterly loss of $0.16 per share, better than the Zacks Consensus Estimate of a loss of $0.19, and an improvement from a loss of $0.32 per share a year ago, resulting in an earnings surprise of +15.79% [1] - The company posted revenues of $0.15 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 51.67%, and a decline from $0.64 million in the same quarter last year [2] - Co-Diagnostics shares have decreased by approximately 47.2% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The earnings outlook for Co-Diagnostics is uncertain, with current consensus EPS estimates at -$0.16 on $0.3 million in revenues for the upcoming quarter and -$0.79 on $0.81 million in revenues for the current fiscal year [7] - The estimate revisions trend for Co-Diagnostics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]